ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – What’s Next?

ImmuCell Co. (NASDAQ:ICCC) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.61 and traded as high as $5.55. ImmuCell shares last traded at $5.39, with a volume of 65,701 shares trading hands.

ImmuCell Stock Performance

The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 3.11. The company has a market cap of $48.42 million, a PE ratio of -10.78 and a beta of 0.39. The company’s 50 day moving average price is $5.08 and its 200-day moving average price is $4.61.

ImmuCell (NASDAQ:ICCC) last issued its earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. The firm had revenue of $7.75 million for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ICCC. Mesirow Financial Investment Management Inc. increased its holdings in ImmuCell by 100.0% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 12,178 shares during the period. Citadel Advisors LLC purchased a new stake in shares of ImmuCell in the 4th quarter valued at about $149,000. Northern Trust Corp boosted its position in shares of ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 14,982 shares during the last quarter. Geode Capital Management LLC increased its position in shares of ImmuCell by 13.9% in the fourth quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after purchasing an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC bought a new position in shares of ImmuCell in the 4th quarter worth $676,000. Institutional investors own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.